S&P 500   3,857.27 (+0.40%)
DOW   31,713.47 (+0.69%)
QQQ   308.06 (-0.20%)
AAPL   120.94 (-0.40%)
MSFT   230.62 (-0.42%)
FB   265.90 (+0.61%)
GOOGL   2,086.00 (-0.53%)
TSLA   603.89 (+0.99%)
AMZN   3,013.77 (+0.44%)
NVDA   498.85 (+0.08%)
BABA   230.00 (-1.66%)
CGC   31.36 (+0.61%)
GE   14.14 (+3.97%)
MU   88.69 (-0.27%)
NIO   37.53 (-1.52%)
AMD   78.15 (-0.47%)
T   29.57 (-0.17%)
F   12.36 (+0.73%)
ACB   9.64 (+0.42%)
DIS   195.47 (+2.88%)
BA   225.96 (+1.23%)
NFLX   514.30 (-0.40%)
PFE   34.39 (+0.00%)
S&P 500   3,857.27 (+0.40%)
DOW   31,713.47 (+0.69%)
QQQ   308.06 (-0.20%)
AAPL   120.94 (-0.40%)
MSFT   230.62 (-0.42%)
FB   265.90 (+0.61%)
GOOGL   2,086.00 (-0.53%)
TSLA   603.89 (+0.99%)
AMZN   3,013.77 (+0.44%)
NVDA   498.85 (+0.08%)
BABA   230.00 (-1.66%)
CGC   31.36 (+0.61%)
GE   14.14 (+3.97%)
MU   88.69 (-0.27%)
NIO   37.53 (-1.52%)
AMD   78.15 (-0.47%)
T   29.57 (-0.17%)
F   12.36 (+0.73%)
ACB   9.64 (+0.42%)
DIS   195.47 (+2.88%)
BA   225.96 (+1.23%)
NFLX   514.30 (-0.40%)
PFE   34.39 (+0.00%)
S&P 500   3,857.27 (+0.40%)
DOW   31,713.47 (+0.69%)
QQQ   308.06 (-0.20%)
AAPL   120.94 (-0.40%)
MSFT   230.62 (-0.42%)
FB   265.90 (+0.61%)
GOOGL   2,086.00 (-0.53%)
TSLA   603.89 (+0.99%)
AMZN   3,013.77 (+0.44%)
NVDA   498.85 (+0.08%)
BABA   230.00 (-1.66%)
CGC   31.36 (+0.61%)
GE   14.14 (+3.97%)
MU   88.69 (-0.27%)
NIO   37.53 (-1.52%)
AMD   78.15 (-0.47%)
T   29.57 (-0.17%)
F   12.36 (+0.73%)
ACB   9.64 (+0.42%)
DIS   195.47 (+2.88%)
BA   225.96 (+1.23%)
NFLX   514.30 (-0.40%)
PFE   34.39 (+0.00%)
S&P 500   3,857.27 (+0.40%)
DOW   31,713.47 (+0.69%)
QQQ   308.06 (-0.20%)
AAPL   120.94 (-0.40%)
MSFT   230.62 (-0.42%)
FB   265.90 (+0.61%)
GOOGL   2,086.00 (-0.53%)
TSLA   603.89 (+0.99%)
AMZN   3,013.77 (+0.44%)
NVDA   498.85 (+0.08%)
BABA   230.00 (-1.66%)
CGC   31.36 (+0.61%)
GE   14.14 (+3.97%)
MU   88.69 (-0.27%)
NIO   37.53 (-1.52%)
AMD   78.15 (-0.47%)
T   29.57 (-0.17%)
F   12.36 (+0.73%)
ACB   9.64 (+0.42%)
DIS   195.47 (+2.88%)
BA   225.96 (+1.23%)
NFLX   514.30 (-0.40%)
PFE   34.39 (+0.00%)
Log in
NASDAQ:SRPT

Sarepta Therapeutics Stock Forecast, Price & News

$84.09
-0.70 (-0.83 %)
(As of 03/8/2021 09:34 AM ET)
Add
Compare
Today's Range
$81.00
Now: $84.09
$85.25
50-Day Range
$82.16
MA: $90.68
$98.24
52-Week Range
$77.01
Now: $84.09
$181.83
Volume588 shs
Average Volume2.60 million shs
Market Capitalization$6.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.01
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta Therapeutics logo

Headlines

Earnings Preview: Sarepta Therapeutics
February 26, 2021 |  benzinga.com
SRPT Feb 2021 99.000 put
February 13, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRPT
Previous SymbolNASDAQ:AVII
CUSIPN/A
Phone617-274-4000
Employees743
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380.83 million
Book Value$10.98 per share

Profitability

Net Income$-715,080,000.00
Net Margins-121.30%

Miscellaneous

Market Cap$6.68 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.93 out of 5 stars

Medical Sector

90th out of 1,968 stocks

Pharmaceutical Preparations Industry

34th out of 771 stocks

Analyst Opinion: 4.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$84.09
-0.70 (-0.83 %)
(As of 03/8/2021 09:34 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

Is Sarepta Therapeutics a buy right now?

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 sell rating, 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sarepta Therapeutics?

Wall Street analysts have given Sarepta Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sarepta Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Sarepta Therapeutics
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its earnings results on Monday, March, 1st. The biotechnology company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.99) by $0.41. The biotechnology company had revenue of $145.10 million for the quarter, compared to the consensus estimate of $145.54 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 61.62% and a negative net margin of 121.30%. The firm's revenue was up 45.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.16) EPS.
View Sarepta Therapeutics' earnings history
.

How has Sarepta Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRPT stock has decreased by 17.5% and is now trading at $84.79.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SRPT?

22 equities research analysts have issued 12-month price objectives for Sarepta Therapeutics' stock. Their forecasts range from $73.00 to $230.00. On average, they anticipate Sarepta Therapeutics' share price to reach $150.48 in the next twelve months. This suggests a possible upside of 77.5% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 58, Pay $1.39M)
  • Mr. William F. Ciambrone, Exec. VP of Technical Operations (Age 57, Pay $438.01k)
  • Mr. David Tyronne Howton Jr., Consultant (Age 49, Pay $731.8k)
  • Dr. Gilmore O'Neill M.D., Exec. VP of R&D and Chief Medical Officer (Age 56, Pay $933.33k)
  • Mr. Ian Michael Estepan, Exec. VP, Principal Financial and Accounting Officer & CFO (Age 45)
  • Dr. Louise Rodino-Klapac Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. Ryan E. Brown, VP, Global Chief Compliance Officer, Regulatory Counsel & Interim Gen. Counsel
  • Dr. Diane L. Berry, Sr. VP of Global Health Policy and Gov. & Patient Affairs
  • Ms. Joan Nickerson M.B.A., Sr. VP of HR
  • Mr. Dallan Murray, Sr. VP & Chief Commercial Officer

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and The Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (4.91%), Avoro Capital Advisors LLC (2.22%), Price T Rowe Associates Inc. MD (1.65%), Sands Capital Management LLC (1.24%), First Trust Advisors LP (0.68%) and Artisan Partners Limited Partnership (0.67%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics
.

Which major investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Sands Capital Management LLC, Janus Henderson Group PLC, Los Angeles Capital Management LLC, First Trust Advisors LP, Price T Rowe Associates Inc. MD, FIL Ltd, and Worldquant Millennium Advisors LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include David T Howton, Hans Lennart Rudolf Wigzell, Joseph Bratica, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
or view top insider-selling stocks.

Which major investors are buying Sarepta Therapeutics stock?

SRPT stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Avidity Partners Management LP, Darwin Global Management Ltd., Avoro Capital Advisors LLC, LMR Partners LLP, TCW Group Inc., Alliancebernstein L.P., and Nuveen Asset Management LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney, and Richard Barry.
View insider buying and selling activity for Sarepta Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $84.79.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics has a market capitalization of $6.73 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics employs 743 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.

Where are Sarepta Therapeutics' headquarters?

Sarepta Therapeutics is headquartered at 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.